Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Tiansuo Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1631-6299; OpenAlex author ID A5013680661. Sources: OpenAlex.

Their work

Papers
61 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
102
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 4 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 4 papers · 2021: 3 papers · 2022: 5 papers · 2023: 11 papers · 2024: 6 papers · 2025: 8 papers · 2026: 7 papers

Papers 50 of 61

  1. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-025-02561-9↗
  2. Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4↗
  3. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  4. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  5. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  6. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-0323↗
  7. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  8. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  9. Prognostic Significance of C-Reactive Protein or Prealbumin in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jss.2024.12.047↗
  10. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2025.102292↗
  11. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Co-author DOI 10.1038/s41422-025-01098-4↗
  12. Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling. Co-author DOI 10.1136/gutjnl-2024-333638↗
  13. Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1158/1078-0432.ccr-24-4300↗
  14. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  15. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  16. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Co-author DOI 10.1016/j.surg.2024.07.047↗
  17. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  18. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  19. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.02.046↗
  20. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  21. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  22. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreati… Last author DOI 10.1002/cnr2.1911↗
  23. Retraction notice to "HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma" [Cancer Lett. 453 (2019… Co-author DOI 10.1016/j.canlet.2023.216059↗
  24. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  25. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Co-author DOI 10.1097/js9.0000000000000425↗
  26. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-1143↗
  27. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  28. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  29. iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy Co-author DOI 10.21203/rs.3.rs-2470450/v1↗
  30. Impact of preoperative CA19-9 and histology grade on prognosis of pancreatic ductal adenocarcinoma and its value in TNM stage Last author DOI 10.21203/rs.3.rs-2653528/v1↗
  31. Biological risk based on preoperative serum CA19-9 and histology grade predicts prognosis in patients with pancreatic cancer Last author DOI 10.22541/au.168681252.23358138/v1↗
  32. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Last author DOI 10.3389/fonc.2023.1276037↗
  33. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215864↗
  34. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Co-author DOI 10.1038/s41416-022-01927-y↗
  35. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Co-author DOI 10.1053/j.gastro.2021.12.249↗
  36. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  37. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.841819↗
  38. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. Co-author DOI 10.1002/jcsm.12692↗
  39. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  40. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Co-author DOI 10.1016/j.canlet.2021.07.024↗
  41. Methylation of HSP70 Orchestrates Its Binding to and Stabilization of BCL2 mRNA and Renders Pancreatic Cancer Cells Resistant to Therapeutics. Co-author DOI 10.1158/0008-5472.can-19-1738↗
  42. Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression. Co-author DOI 10.3892/ol.2019.11157↗
  43. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.33767↗
  44. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Co-author DOI 10.7150/thno.42416↗
  45. RETRACTED: HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.03.036↗
  46. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗
  47. LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Co-author DOI 10.1158/1078-0432.ccr-18-3533↗
  48. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of … Co-author DOI 10.1053/j.gastro.2017.09.039↗
  49. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Co-author DOI 10.1038/ncomms14035↗
  50. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/onc.2016.458↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 48 shared papers, 2011–2026 · strength 6.09
  2. Xiuchao Wang · 46 shared papers, 2011–2026 · strength 5.99
  3. Chongbiao Huang · 32 shared papers, 2015–2026 · strength 4.21
  4. Song Gao · 28 shared papers, 2012–2026 · strength 3.61
  5. Shengyu Yang · 23 shared papers, 2016–2026 · strength 2.88
  6. Chuntao Gao · 16 shared papers, 2014–2026 · strength 2.44
  7. Yongjie Xie · 13 shared papers, 2022–2026 · strength 2.33
  8. Jing Liu · 15 shared papers, 2019–2026 · strength 2.18
  9. Tianxing Zhou · 13 shared papers, 2019–2026 · strength 2.17
  10. Yuexiang Liang · 7 shared papers, 2023–2026 · strength 1.48
  11. Jun Yu · 7 shared papers, 2024–2026 · strength 1.39
  12. Shaofei Chang · 7 shared papers, 2023–2025 · strength 1.38
  13. Haorui Li · 6 shared papers, 2023–2025 · strength 1.24
  14. Zengxun Li · 9 shared papers, 2017–2026 · strength 1.17
  15. Yukuan Feng · 6 shared papers, 2024–2026 · strength 1.16
  16. Huizhi Sun · 7 shared papers, 2021–2026 · strength 1.15
  17. Quan Man · 5 shared papers, 2023–2025 · strength 0.98
  18. Yiping Zou · 5 shared papers, 2023–2025 · strength 0.93
  19. Chao Xu · 5 shared papers, 2023–2026 · strength 0.91
  20. Shangheng Shi · 4 shared papers, 2026 · strength 0.80
  21. Chao Yang · 4 shared papers, 2025–2026 · strength 0.80
  22. Liangliang Wu · 6 shared papers, 2019–2025 · strength 0.78
  23. Xugang Sun · 4 shared papers, 2021–2025 · strength 0.74
  24. Danqi Fu · 5 shared papers, 2019–2025 · strength 0.71
  25. Wenna Jiang · 6 shared papers, 2017–2024 · strength 0.71

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.